104 related articles for article (PubMed ID: 26513874)
21. The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
Heubner M; Wimberger P; Riemann K; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Oncol Res; 2010; 18(7):343-7. PubMed ID: 20377136
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
Li J; Zhang Y; Gao Y; Cui Y; Liu H; Li M; Tian Y
Oncol Rep; 2014 Sep; 32(3):979-88. PubMed ID: 24968817
[TBL] [Abstract][Full Text] [Related]
23. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
24. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
O'Donnell T; Christie EL; Ahuja A; Buros J; Aksoy BA; Bowtell DDL; Snyder A; Hammerbacher J
BMC Cancer; 2018 Jan; 18(1):87. PubMed ID: 29357823
[TBL] [Abstract][Full Text] [Related]
26. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
28. A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
Song J; Zhang W; Wang S; Liu K; Song F; Ran L
Int J Oncol; 2018 Aug; 53(2):866-876. PubMed ID: 29749482
[TBL] [Abstract][Full Text] [Related]
29. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gagno S; Poletto E; Bartoletti M; Quartuccio L; Romualdi C; Garziera M; Scalone S; Sorio R; Dreussi E; Zanusso C; De Mattia E; Roncato R; Cecchin E; Giorda G; De Vita S; Dal Bo M; Puglisi F; Toffoli G
Gynecol Oncol; 2020 Jan; 156(1):233-242. PubMed ID: 31711657
[TBL] [Abstract][Full Text] [Related]
30. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
Obata H; Yahata T; Quan J; Sekine M; Tanaka K
Anticancer Res; 2006; 26(3B):2227-32. PubMed ID: 16821592
[TBL] [Abstract][Full Text] [Related]
31. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
32. Impact of platinum on the whole mitochondrial genome of ovarian carcinomas both in vivo and in vitro.
Shi H; Pan L; Song T
Int J Gynecol Cancer; 2009 Apr; 19(3):423-30. PubMed ID: 19407571
[TBL] [Abstract][Full Text] [Related]
33. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
34. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
36. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract][Full Text] [Related]
37. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
38. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
39. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]